Prolia (Denosumab) vs Evenity (Romosozumab): Head-to-Head Efficacy

What Are These Two Drugs and How Do They Work?

Denosumab (Prolia) and romosozumab (Evenity) both reduce osteoporotic fractures but through completely different mechanisms. Denosumab blocks RANK-L, the signaling protein that activates osteoclasts, slowing bone resorption. Romosozumab inhibits sclerostin, a protein that normally suppresses bone formation, which simultaneously increases bone building and decreases bone breakdown.

Denosumab: Mechanism and Approval History

Denosumab is a fully human monoclonal antibody that binds RANK-L with high affinity, preventing osteoclast maturation. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, based primarily on the FREEDOM trial. Prescribing information is available via FDA.

Because osteoclast suppression is reversible and RANK-L levels rebound quickly after the drug clears, discontinuation without a transition to an antiresorptive agent causes rapid bone loss and a well-documented rebound fracture risk. This biology shapes every clinical decision around denosumab sequencing.

Romosozumab: Mechanism and Approval History

Romosozumab is a humanized monoclonal antibody against sclerostin. By blocking sclerostin, it disinhibits Wnt signaling inside osteoblasts, driving bone formation while also modestly reducing resorption markers. The FDA approved it in April 2019 specifically for postmenopausal women with osteoporosis at high or very high fracture risk, with a black-box warning for patients who have had a myocardial infarction or stroke in the preceding 12 months. See the FDA label.

Treatment is strictly capped at 12 months. After that window, sclerostin levels rebound and the anabolic effect disappears, so clinicians must transition patients to an antiresorptive agent to preserve the gains.

Fracture Efficacy: What the Key Trials Actually Show

Neither drug has been tested against the other in a single randomized controlled trial. Comparing them requires reading across separate large phase 3 programs, each with different comparators and patient populations.

FREEDOM Trial: Denosumab vs Placebo

FREEDOM (N=7,868) enrolled postmenopausal women with a lumbar spine or total hip T-score between -2.5 and -4.0. Over 36 months, denosumab 60 mg every 6 months reduced new vertebral fractures by 68% versus placebo (relative risk 0.32; 95% CI 0.26-0.41; P<0.001) [1]. Hip fracture risk fell by 40% (hazard ratio 0.60; 95% CI 0.37-0.97) and nonvertebral fracture risk dropped by 20%.

Lumbar spine BMD increased 9.2% from baseline and total hip BMD increased 6.0% at 36 months versus placebo-treated controls.

ARCH Trial: Romosozumab vs Alendronate

ARCH (N=4,093) enrolled postmenopausal women with a prior vertebral fracture and at least one additional risk factor. Participants received either romosozumab 210 mg monthly for 12 months followed by alendronate, or alendronate throughout. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% versus alendronate alone (odds ratio 0.52; 95% CI 0.40-0.66; P<0.001) [2]. Clinical fracture risk fell by 27% and nonvertebral fracture risk by 19%.

FRAME Trial: Romosozumab vs Placebo

FRAME (N=7,180) provides the most direct efficacy signal for romosozumab against an untreated control. Over 12 months, romosozumab reduced new vertebral fractures by 73% versus placebo see PubMed. Lumbar spine BMD rose 13.7% at 12 months, roughly 2.5 times the gain seen with denosumab over the same interval in FREEDOM.

Reading Across Trials: Where Does This Leave Clinicians?

Cross-trial comparisons carry inherent limitations because baseline T-scores, fracture history, and prior treatment vary. With that caveat stated clearly, the pattern across programs suggests:

• Romosozumab delivers substantially larger BMD gains at 12 months, particularly at the lumbar spine.
• Denosumab shows comparable or superior long-term fracture reduction when continued beyond 12 months, because it can be administered indefinitely.
• The 68% vertebral fracture reduction in FREEDOM (vs placebo) and the 73% reduction in FRAME (vs placebo, 12 months) are numerically similar, meaning both agents reach an approximately equivalent floor of short-term vertebral fracture protection.

The practical difference is time. Romosozumab gets there faster. Denosumab holds the position longer.

BMD Gains: 12-Month and Long-Term Data

Bone mineral density is a surrogate endpoint, but regulatory agencies and guidelines use it as a reliable fracture-risk proxy when fracture data are limited.

12-Month BMD Comparison

At 12 months, romosozumab increases lumbar spine BMD by approximately 13.7% from baseline in the FRAME trial. Denosumab, over the same interval in the FREEDOM extension, produces roughly 5-6% lumbar spine gain. The difference is not trivial. It reflects romosozumab's dual mechanism: it builds bone at the same time it reduces resorption, while denosumab only suppresses resorption.

Total hip gains show a similar pattern. Romosozumab produced a 6.9% hip BMD increase at 12 months in FRAME versus roughly 3.4% with denosumab over the same interval.

Long-Term BMD With Denosumab

The FREEDOM extension study followed patients for up to 10 years of continuous denosumab. Lumbar spine BMD rose progressively, reaching 21.7% above baseline at 10 years see FREEDOM extension on PubMed. No plateau was observed. This is a meaningful advantage: denosumab appears to keep building BMD as long as treatment continues, which no other antiresorptive agent has demonstrated at this duration.

What Happens After Romosozumab Stops

Romosozumab's anabolic effect is time-limited. Sclerostin rebounds after the drug clears, and without immediate antiresorptive follow-up, BMD gains from the 12-month course erode within 12-18 months. The ARCH design exploited this biology correctly: romosozumab for 12 months, then alendronate to lock in the gains. Substituting denosumab as the follow-on agent after romosozumab has become a common clinical practice, though direct comparative data on which antiresorptive best preserves the gains remain limited.

Safety Profiles: Where the Drugs Diverge Most

Both agents share class-level risks common to potent osteoporosis therapies, including osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF). Their divergent safety signals, though, are what drive patient selection.

Cardiovascular Signal With Romosozumab

The ARCH trial recorded serious cardiovascular events in 2.5% of romosozumab recipients versus 1.9% of alendronate recipients over 12 months (adjudicated cardiac ischemic events and cerebrovascular events combined) [2]. The difference was statistically significant and prompted the FDA black-box warning. The mechanism is not established, but sclerostin may play a cardioprotective role in vascular smooth muscle, and inhibiting it could theoretically increase arterial calcification. Patients with a myocardial infarction or stroke in the prior 12 months should not receive romosozumab.

Rebound Fracture Risk With Denosumab Discontinuation

Stopping denosumab without a bridging antiresorptive causes rapid RANK-L rebound. Case series and pharmacovigilance reports describe multiple vertebral fractures occurring within 8-16 months of the last dose. The American Society for Bone and Mineral Research (ASBMR) issued a task force report highlighting this risk and recommending bisphosphonate or other antiresorptive therapy within 5-6 months of the final denosumab injection see ASBMR guidance on PubMed.

Shared Risks: ONJ and AFF

Both drugs carry low but real risks of osteonecrosis of the jaw and atypical femoral fracture. These risks appear to be duration- and dose-dependent. With denosumab, the absolute risk of ONJ is approximately 0.7-1.9 per 10,000 patient-years in osteoporosis doses (substantially lower than oncology doses). AFF risk rises with treatment duration beyond 5 years, which is one argument for drug holidays in appropriate patients. Romosozumab's 12-month cap limits cumulative exposure to these risks.

Hypocalcemia

Both agents can cause hypocalcemia, particularly in patients with vitamin D deficiency or chronic kidney disease. Correcting 25-hydroxyvitamin D to at least 20 ng/mL and ensuring adequate calcium intake before starting either drug is standard practice per Endocrine Society guidelines.

Which Patients Benefit Most From Each Drug?

Selecting between these two agents is not a single-variable decision. Fracture history, cardiovascular history, prior medication exposure, and the patient's ability to commit to follow-on therapy all matter.

When to Consider Romosozumab First

The Endocrine Society and the American Association of Clinical Endocrinology (AACE) both recognize romosozumab as an appropriate first-line choice for patients at very high fracture risk, defined as a recent fragility fracture (within the past 12 months), T-score below -3.0, or multiple vertebral fractures see AACE 2020 guidelines.

A practical framework for selecting romosozumab over denosumab as the initial agent:

1. The patient has a T-score at or below -3.0 at the lumbar spine or hip.
2. She has sustained a vertebral fracture within the past 12 months, indicating very high imminent refracture risk.
3. No myocardial infarction or stroke in the preceding 12 months.
4. The patient can reliably commit to monthly injections for 12 months and then transition to an antiresorptive agent.
5. The treating clinician has a clear plan for post-romosozumab therapy before the first injection is given.

If all five conditions are met, romosozumab's faster, larger BMD gains may reduce fracture risk more rapidly than any antiresorptive started at the same time.

When to Choose Denosumab

Denosumab fits well for patients at high (but not imminent) fracture risk who need long-term, continuous management. It is also the preferred agent when:

• The patient has a history of cardiovascular disease that makes romosozumab contraindicated.
• The patient prefers a twice-yearly injection schedule over monthly visits.
• Long-term BMD accumulation over 5-10 years is a treatment goal (supported by the FREEDOM extension data).
• The patient has already completed a course of romosozumab and needs a follow-on antiresorptive.

Patients Who Have Been on Bisphosphonates

Prior alendronate or zoledronate blunts romosozumab's anabolic response. A subgroup analysis from FRAME showed that patients who had received prior bisphosphonates had attenuated BMD gains compared with treatment-naive patients. Denosumab is less affected by prior bisphosphonate exposure and remains a viable option regardless of prior therapy history. Clinicians should confirm prior medication history before choosing romosozumab in patients who have received any bisphosphonate in the preceding 2-3 years.

Switching Between Denosumab and Romosozumab

Sequencing is where the clinical nuance is greatest.

Going From Denosumab to Romosozumab

Moving from denosumab to romosozumab is not standard practice and carries theoretical risk. The RANK-L rebound that follows denosumab discontinuation may occur even when romosozumab is initiated promptly, because romosozumab does not directly suppress RANK-L. There are no large randomized trials evaluating this specific transition. Individual case reports and small series suggest the switch may produce inadequate BMD protection in the gap period. Until prospective data are available, most bone specialists recommend transitioning from denosumab to a bisphosphonate rather than to romosozumab.

Going From Romosozumab to Denosumab

This sequence is well-supported. After the 12-month romosozumab course, initiating denosumab has been studied in the FRAME extension: patients who transitioned from romosozumab to denosumab continued to gain BMD at the lumbar spine and hip, with no attenuation of the gains built during the romosozumab course. The AACE 2020 guidelines list this as an appropriate and preferred sequence for patients at very high risk who need sustained protection after romosozumab.

Going From Bisphosphonate to Romosozumab to Denosumab

This three-step sequence ("anabolic first, then maintain") represents a more aggressive strategy for patients with very high fracture risk and prior bisphosphonate exposure. It has not been tested as a formal three-arm protocol, but the biology is supported: zoledronate prior to romosozumab has shown partial attenuation, so the preferred approach in practice is to allow a bisphosphonate washout before starting romosozumab when possible.

Cost, Access, and Patient Burden

Neither drug is inexpensive. Romosozumab's list price in the United States is approximately $1,800-$2,100 per monthly injection, making the 12-month course roughly $22,000-$25,000 before insurance adjustments. Denosumab lists at approximately $1,600-$1,900 per twice-yearly injection, or about $3,200-$3,800 per year, which makes it substantially more economical for long-term use.

Insurance coverage for romosozumab frequently requires prior authorization and documentation of a T-score at or below -2.5 with a fracture history or T-score at or below -3.0. Denosumab coverage is generally less restrictive and available with a T-score diagnosis of osteoporosis alone.

Both drugs require subcutaneous administration. Romosozumab's monthly cadence represents a higher patient-visit burden over 12 months, though the fixed endpoint simplifies long-term planning. Denosumab's every-6-month schedule is convenient but demands indefinite continuation with no clean stopping point, which places a substantial coordination burden on practices to avoid inadvertent gaps.

Head-to-Head Summary: Key Differences at a Glance

| Parameter | Denosumab (Prolia) | Romosozumab (Evenity) | |---|---|---| | Mechanism | Antiresorptive (RANK-L inhibitor) | Dual anabolic + antiresorptive (sclerostin inhibitor) | | Dosing | 60 mg SC every 6 months, indefinite | 210 mg SC monthly, 12 months only | | Vertebral fracture reduction | 68% vs placebo (FREEDOM) | 48% vs alendronate (ARCH); 73% vs placebo (FRAME) | | 12-month lumbar spine BMD gain | ~5-6% above baseline | ~13.7% above baseline | | Cardiovascular warning | None specific | Black box: avoid if MI or stroke within 12 months | | Discontinuation risk | Rebound fracture if stopped without bridging | BMD loss if not followed by antiresorptive | | Long-term data | 10-year FREEDOM extension | 24-month post-romosozumab follow-on data | | Approved indication | Postmenopausal osteoporosis (also male and glucocorticoid-induced) | Postmenopausal osteoporosis at high/very high risk | | Cost (annual, approximate) | ~$3,200-$3,800 | ~$22,000-$25,000 (12-month course only) |

Clinical Guidelines: What the Major Organizations Recommend

The Endocrine Society's 2019 clinical practice guideline on osteoporosis recommends anabolic therapy (including romosozumab) as first-line treatment for patients at very high fracture risk, defined as a recent major osteoporotic fracture, T-score below -3.0, or very high FRAX score. For high (not very high) risk, antiresorptive therapy including denosumab is appropriate as first-line. The guideline states explicitly: "For women with postmenopausal osteoporosis at very high risk of fracture, we suggest initiating treatment with an anabolic agent rather than antiresorptive therapy." Endocrine Society 2019 guideline.

The AACE/ACE 2020 Clinical Practice Guidelines define very high fracture risk separately from high fracture risk and place romosozumab alongside teriparatide and abaloparatide as first-choice agents for the very-high-risk tier AACE guidelines. Denosumab sits in the high-risk tier as an alternative to oral bisphosphonates.

Neither organization has issued a direct head-to-head recommendation because no head-to-head trial data exist. Both acknowledge the cross-trial nature of any efficacy comparison and call for individualized decision-making based on fracture history, comorbidities, and patient preferences.